当前位置:首页 - 行情中心 - 海尔生物(688139) - 财务分析 - 现金流量表

海尔生物

(688139)

  

流通市值:109.51亿  总市值:109.51亿
流通股本:3.16亿   总股本:3.16亿

现金流量表

报告期2026-06-302026-03-312025-12-312025-09-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金1,250,361,495.99574,350,307.752,444,397,545.971,681,571,829.29
  收到的税费返还22,665,711.9711,370,131.9338,320,562.7628,202,468.03
  收到其他与经营活动有关的现金23,396,106.1315,551,245.6554,358,007.7949,860,321.29
  经营活动现金流入小计1,296,423,314.09601,271,685.332,537,076,116.521,759,634,618.61
  购买商品、接受劳务支付的现金573,478,294.19274,950,369.931,193,137,579.66880,864,392.6
  支付给职工以及为职工支付的现金348,478,896.68185,693,586.39647,242,346.78481,731,863.06
  支付的各项税费82,046,652.258,510,149.45138,101,835.69101,364,948.85
  支付其他与经营活动有关的现金148,143,900.2970,440,352.21290,699,981.21213,030,277.78
  经营活动现金流出小计1,152,147,743.36589,594,457.982,269,181,743.341,676,991,482.29
  经营活动产生的现金流量净额144,275,570.7311,677,227.35267,894,373.1882,643,136.32
二、投资活动产生的现金流量:
  收回投资收到的现金1,954,760,000783,440,0003,955,764,141.173,139,860,000
  取得投资收益收到的现金17,455,109.231,778,538.1622,067,445.8917,124,148.91
  处置固定资产、无形资产和其他长期资产收回的现金净额88,584.08100455,473.89358,280
  投资活动现金流入小计1,972,303,693.31785,218,638.163,978,287,060.953,157,342,428.91
  购建固定资产、无形资产和其他长期资产支付的现金35,790,899.1215,578,197.98119,254,456.2480,869,727.09
  投资支付的现金1,794,190,000526,100,0003,785,640,0002,944,800,000
  取得子公司及其他营业单位支付的现金--56,647,50056,647,500
  支付其他与投资活动有关的现金1,553,420---
  投资活动现金流出小计1,831,534,319.12541,678,197.983,961,541,956.243,082,317,227.09
  投资活动产生的现金流量净额140,769,374.19243,540,440.1816,745,104.7175,025,201.82
三、筹资活动产生的现金流量:
  吸收投资收到的现金3,731,201.76-225,000-
  其中:子公司吸收少数股东投资收到的现金3,731,201.76-225,000-
  取得借款收到的现金10,000,0005,000,00020,000,00020,000,000
  收到其他与筹资活动有关的现金--717,966,461.12538,303,291.65
  筹资活动现金流入小计13,731,201.765,000,000738,191,461.12558,303,291.65
  偿还债务支付的现金10,010,0005,010,00010,010,00010,000,000
  分配股利、利润或偿付利息支付的现金105,778,234.17153,575.33150,295,702.61148,510,068.41
  其中:子公司支付给少数股东的股利、利润2,286,500-2,938,276.5-
  支付其他与筹资活动有关的现金3,668,255.221,469,892.73846,622,175.04645,325,067.21
  筹资活动现金流出小计119,456,489.396,633,468.061,006,927,877.65803,835,135.62
  筹资活动产生的现金流量净额-105,725,287.63-1,633,468.06-268,736,416.53-245,531,843.97
四、汇率变动对现金及现金等价物的影响-8,907,018.78-7,434,796.113,199,531.71,655,825.71
五、现金及现金等价物净增加额170,412,638.51246,149,403.3619,102,593.06-86,207,680.12
  加:期初现金及现金等价物余额553,806,623.74553,806,623.74534,704,030.68534,704,030.68
  期末现金及现金等价物余额724,219,262.25799,956,027.1553,806,623.74448,496,350.56
补充资料:
  净利润148,915,536.8-255,132,280.57-
  资产减值准备2,239,082.03-8,507,764.46-
  固定资产和投资性房地产折旧36,981,509.15-71,800,978.78-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧36,597,186.65-71,032,333.78-
    投资性房地产折旧384,322.5-768,645-
  无形资产摊销24,337,800.45-48,373,937.95-
  长期待摊费用摊销1,087,642.91-2,328,495.2-
  递延收益摊销-1,520,476--3,263,645.16-
  处置固定资产、无形资产和其他长期资产的损失102,532.28--632,148.71-
  固定资产报废损失63,671.06-1,225,721.96-
  公允价值变动损失-2,224,070.28-494,110.38-
  财务费用-471,146.53--21,561,678.65-
  投资损失-5,829,691.33--27,308,983.33-
  递延所得税-12,812,076.06--31,895,649.67-
  其中:递延所得税资产减少-10,396,413.94--23,666,047.65-
    递延所得税负债增加-2,415,662.12--8,229,602.02-
  存货的减少9,291,842.66--18,645,073.77-
  经营性应收项目的减少-36,476,468.16--68,683,543.49-
  经营性应付项目的增加-25,376,942.06-34,073,537.69-
  现金的期末余额724,219,262.25-553,806,623.74-
  减:现金的期初余额553,806,623.74-534,704,030.68-
  现金及现金等价物的净增加额170,412,638.51-19,102,593.06-
公告日期2026-08-202026-04-302026-03-282025-10-31
审计意见(境内)标准无保留意见
TOP↑